Solasia goes to market

Solasia becomes Japan’s first public biotech in months and looks to China

After becoming the first Japanese biotech to go public in 18 months, Solasia Pharma K.K. (Tokyo:4597) plans to use the proceeds to prepare to launch its first products in China.

Solasia raised ¥3.6 billion ($32 million) through the sale of 19.4

Read the full 417 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE